Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients

@article{Sun2013EarlystageCE,
  title={Early‐stage comparative effectiveness: Randomized controlled trial with histamine inverse agonist MK‐7288 in excessive daytime sleepiness patients},
  author={H. Sun and C. Macleod and Kate Mostoller and C. Mahon and L. Han and J. Renger and J. Ma and K. R. Brown and V. Schulz and G. Kay and W. J. Herring and C. Lines and L. Rosen and M. G. Murphy and J. Wagner},
  journal={The Journal of Clinical Pharmacology},
  year={2013},
  volume={53}
}
  • H. Sun, C. Macleod, +12 authors J. Wagner
  • Published 2013
  • Medicine
  • The Journal of Clinical Pharmacology
  • Histaminergic neurons are regulators of the sleep–wake cycle. We evaluated the alerting effects of MK‐7288 (10, 20 mg), a novel histamine‐3 receptor inverse agonist (H3RIA), along with modafinil (200 mg), a standard treatment, in a randomized, double‐blind, placebo controlled, crossover study of 56 patients with excessive daytime sleepiness (EDS). Efficacy was assessed using maintenance of wakefulness tests (MWT) and car driving simulation tests. MK‐7288 and modafinil significantly prolonged… CONTINUE READING
    6 Citations

    References

    SHOWING 1-10 OF 42 REFERENCES
    Maintenance of wakefulness test in obstructive sleep apnea syndrome.
    • 145
    ACNS Clinical Controversy: MSLT and MWT Have Limited Clinical Utility
    • M. Bonnet
    • Psychology, Medicine
    • Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
    • 2006
    • 44
    The clinical use of the MSLT and MWT.
    • 295
    • PDF
    Histamine H3 antagonists as wake-promoting and pro-cognitive agents.
    • 45
    Multiple sleep latency test and maintenance of wakefulness test.
    • 63
    • PDF
    Modafinil: A Review of Neurochemical Actions and Effects on Cognition
    • 530
    • PDF
    The histamine H3 receptor: from discovery to clinical trials with pitolisant
    • 202